<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216865</url>
  </required_header>
  <id_info>
    <org_study_id>MSCDF001</org_study_id>
    <nct_id>NCT01216865</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot</brief_title>
  <official_title>Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether umbilical cord Mesenchymal Stem Cells of
      treatment for diabetic foot is safe and effective in the management of diabetic foot
      ischemia, the therapeutic effect of stem cells is caused by improving blood circulation in
      ischemic limb which would in turn promote ulcer healing, prevent amputation of limb and
      relieve the Sevier pain of ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetic patients with diabetic foot were enrolled and randomized to either
      transplanted group or control group. Patients in transplanted group received the stem cells
      treatment,Patients in control group received the standard treatment. After culture in vitro,
      umbilical cord mesenchymal stem cells should go through safety evaluation which include
      culture and check of pathogenic microorganisms (bacteria, mycoplasma, chlamydia, eumycete and
      viruses) of the cells medium and karyotype analysis of the mesenchymal stem cells. Only the
      safe cells were harvested and transplanted by multiple intramuscular injections into the
      impaired lower limbs. Follow-up index include: efficacy (pain,ulcer healing rate, lower limb
      amputation rate and ,ankle-brachial index,magnetic resonance angiography,electromyogram) and
      safety (infection of the injection site, fever, and tumour generation).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic evaluation of angiogenesis at ischemic limb</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial pressure index</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing (wound size, wound stage)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking distance</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and extent of amputations</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetic Foot</condition>
  <condition>Critical Limb Ischemia</condition>
  <condition>Mesenchymal Stem Cells</condition>
  <condition>Umbilical Cord</condition>
  <arm_group>
    <arm_group_label>umbilical cord mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Any therapy for diabetic foot which is routinely practiced and accepted in China</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical cord mesenchymal stem cells</intervention_name>
    <description>5*10/7 per ischemic limb</description>
    <arm_group_label>umbilical cord mesenchymal stem cells</arm_group_label>
    <other_name>mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc</description>
    <arm_group_label>Standard Therapy</arm_group_label>
    <other_name>Drug therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus Type 2

          -  Age 18 - 75 years

          -  Subject has an Ankle-brachial index &lt; 0.9

          -  Subject has had previous conservative treatment which resulted in little or no
             improvement

          -  Subject has had no stem cell treatment within the past 6 months

          -  No sufficient response to best standard care delivered for six weeks.

          -  No surgical or radiological interventional option for revascularisation as confirmed
             by a vascular surgeon and an interventional radiologist

          -  Signed informed consent

          -  Absence of life-threatening complications from the ischemic limb

          -  Life expectancy more than 2 years

          -  Negative pregnancy test when applicable

        Exclusion Criteria:

          -  Diabetic retinopathy

          -  History of neoplasm or hematological disease

          -  Uncontrolled high blood pressure (&gt;180/110)

          -  Severe cardiac insufficiency (New York Heart Association [NYHA] IV) or ejection
             fraction&lt;30%

          -  Malignant ventricular arrythmia

          -  Deep venous thrombosis during the last 3 months

          -  Active bacterial infection

          -  Body mass index &gt; 35 Kg/m2

          -  Stroke or myocardial infarction during the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yangang Wang, MD Phd</last_name>
    <role>Study Director</role>
    <affiliation>The Affiliated Hospital of Medical College of Qingdao University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianxia Hu, MD</last_name>
    <phone>86-0532-82911676</phone>
    <email>qdyxyhjx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Gao, MS</last_name>
    <phone>86-0532-82911676</phone>
    <email>honggaogloria@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stem Cell Research Center of Medical School Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianxia Hu, MD</last_name>
      <phone>86-0532-82911676</phone>
      <email>qdyxyhjx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Hong Gao, MS</last_name>
      <phone>86-0532-82911676</phone>
      <email>honggaogloria@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yangang Wang, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>October 12, 2010</last_update_submitted>
  <last_update_submitted_qc>October 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wang, Yangang MD</name_title>
    <organization>Stem Cell Research Center of Medical School Hospital of Qingdao University</organization>
  </responsible_party>
  <keyword>Diabetic foot</keyword>
  <keyword>critical limb ischemia</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>umbilical cord</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

